

Dupe! cite! the same as one submitted or

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>			Complete if Known	
			Application Number	10/743,613
			Filing Date	December 22, 2003
			First Name Inventor	Paul Spurr
Sheet	1	of	2	Attorney Docket Number

MAR 26 2004

~~U.S. PATENT DOCUMENTS~~

Examiner Initials'	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ³ (if known)		
BS	A1	5,099,021		Worther et al	03/24/1992
	A2	3,725,428		Janiak, S.	04/03/1973
	A3	4,028,374		Pelosi, Jr. et al.	06/07/1977
BS	A4	6,521,754		Alanine, et al.	02/18/2003

~~FOREIGN PATENT DOCUMENTS~~

Examiner Initials'	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ²	Number ²	Kind Code ³ (if known)		
BS	B1	WO	01/97786		F.Hoffmann-La Roche AG	12/27/2001
	B2	EP	0 282 971		Warner Lambert Co.	09/21/1988
	B3	EP	0 529 600		Hoechst Aktiengesellschaft	03/03/1993
	B4	EP	0 427 963		Worther et al	05/22/1991
	B5	EP	0 295 656		Abe, S. et al	12/21/1988
	B6	DE	1953149		Ciba AG	05/06/1970
	B7	WO	00/18767		He, X. et al	04/06/2000
	B8	GB	1 345 552A		Societe Nationale De Petroles D'Aquitaine	01/30/1974
	B9	FR	2 753 970 a		Synethelabo	04/03/1998
	B10	EP	0199400A		Jansen Pharmaceuticals	10/29/1986
	B11	GB	1 538 822A		Boehringer Mannheim	01/24/1979
	B12	WO	00/27819A		Novartis AG	05/18/2000
	B13	EP	0 404 440		Pfizer Inc.	12/27/1990
	B14	EP	0 604 657		Otsuka Pharma Co.	07/06/1994
	B15	EP	0 343 893		Pfizer Inc.	11/29/1989
	B16	WO	99/24035		Squibb Bristol Myers	05/10/1999
	B17	WO	01/19360a2		Can-Fite Technologies	09/08/2000
BS	B18	WO	99/37630		Versicor Inc.	01/22/1990

Examiner Signature

Date Considered

~~also recd~~

03/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

MAR 26 2004

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 2 Of 2 Attorney Docket Number 21436 US

Complete if Known

Application Number	10/743,613
Filing Date	December 22, 2003
First Name Inventor	Paul Spurr

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>BS</i>	C1	Forlani, L. et al., <i>J. Heterocyclic Chem.</i> Vol. 37, 2000 pgs. 63-69	
	C2	McDonald, F. et al., <i>Synthesis</i> 2000, No. 7, pgs. 970-974	
	C3	Abstract corresponding to EP 0 529 600 (Document B3)	
	C4	Colotta, V. et al., <i>Arch. Pharm. Med. Chem.</i> , 332 (1999) pgs. 39-41	
	C5	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 39 (1996) pgs. 1164-1171	
	C6	Li, A. H. et al., <i>J. Med. Chem.</i> , 42 (1999) pgs. 706-721	
	C7	Kim, Y. C. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2835-2845	
	C8	Li, A. H. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 3186-3201	
	C9	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2126-2133	
	C10	Poulsen, S. A. et al., <i>Bioorganic & Medicinal Chemistry</i> , 6 (1998) pgs. 619-641	
	C11	Müller, C. E. et al., <i>Bioorganic & Medicinal Chemistry</i> , 6 (1998) pgs. 707-719	
	C12	Patent Abstracts of Japan, Vol. 1999, No. 10, JP 11 130761a	
	C13	Pandeya, Surendra N. et al., <i>Indian Drugs</i> (1985), 23(3), 146-51 XP0080000199	
	C14	Daidone, G. et al., Vol. 44, No. 5 (1989), pgs. 465-473, XP001053114	
	C15	The Merck Index 12 th Ed. (1996) p. 506	
	C16	Abstract corresponding to FR 2 753 970 (Document B9)	
<i>BS</i>	C17	Abstract corresponding to WO 00/27819 (Document B12)	
Examiner Signature	<i>Kamal Saeed</i>		DATE CONSIDERED 03/14/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

140357

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

Substitute for form 1449A/TTO **MAY 24 2006**

O I P E JC53

Complete if Known

Application Number	10/743,613
Filing Date	December 22, 2003
First Name Inventor	Paul Spurr
Art Unit:	1614-1626

Sheet 1 of 2 Attorney Docket Number 21436 US

U.S. PATENT DOCUMENTS

Examiner Initials'	Cite No.'	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
KJ	A1	5,099,021		Worther et al	03/24/1992
J	A2	3,725,428		Janiak, S.	04/03/1973
J	A3	4,028,374		Pelosi, Jr. et al.	06/07/1977
B	A4	6,521,754		Alanine, et al.	02/18/2003

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No.'	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
BS	B1	WO	01/97786		F.Hoffmann-La Roche AG	12/27/2001	
	B2	EP	0 282 971		Warner Lambert Co.	09/21/1988	
	B3	EP	0 529 600		Hoechst Aktiengesellschaft	03/03/1993	
	B4	EP	0 427 963		Worther et al	05/22/1991	
	B5	EP	0 295 656		Abe, S. et al	12/21/1988	
	B6	DE	1953149		Ciba AG	05/06/1970	
	B7	WO	00/18767		He, X. et al	04/06/2000	
	B8	GB	1 345 552A		Societe Nationale De Petroles D'Aquitaine	01/30/1974	
	B9	FR	2 753 970 a		Synethelabo	04/03/1998	
	B10	EP	0199400A		Jansen Pharmaceuticals	10/29/1986	
	B11	GB	1 538 822A		Boehringer Mannheim	01/24/1979	
	B12	WO	00/27819A		Novartis AG	05/18/2000	
	B13	EP	0 404 440		Pfizer Inc.	12/27/1990	
	B14	EP	0 604 657		Otsuka Pharma Co.	07/06/1994	
	B15	EP	0 343 893		Pfizer Inc.	11/29/1989	
	B16	WO	99/24035		Squibb Bristol Myers	05/10/1999	
	B17	WO	01/19360a2		Can-Fite Technologies	09/08/2000	
k	B18	WO	99/37630		Versicor Inc.	01/22/1990	

Examiner Signature Date Considered

Kamal Soeed

03/14/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	10/743,613
				Filing Date	December 22, 2003
				First Name Inventor	Paul Spurr
				Art Unit:	1614 1626
Sheet	2	of	2	Attorney Docket Number	21436 US


NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BS	C1	Forlani, L. et al., <i>J. Heterocyclic Chem.</i> Vol. 37, 2000 pgs. 63-69	
	C2	McDonald, F. et al., <i>Synthesis</i> 2000, No. 7, pgs. 970-974	
	C3	Abstract corresponding to EP 0 529 600 (Document B3) 03/1993	
	C4	Colotta, V. et al., <i>Arch. Pharm. Med. Chem.</i> , 332 (1999) pgs. 39-41	
	C5	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 39 (1996) pgs. 1164-1171	
	C6	Li, A. H. et al., <i>J. Med. Chem.</i> , 42 (1999) pgs. 706-721	
	C7	Kim, Y. C. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2835-2845	
	C8	Li, A. H. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 3186-3201	
	C9	Baraldi, P. G. et al., <i>J. Med. Chem.</i> , 41 (1998) pgs. 2126-2133	
	C10	Poulsen, S. A. et al., <i>Bioorganic & Medicinal Chemistry</i> , 6 (1998) pgs. 619-641	
	C11	Müller, C. E. et al., <i>Bioorganic & Medicinal Chemistry</i> , 6 (1998) pgs. 707-719	
	C12	Patent Abstracts of Japan, Vol. 1999, No. 10, JP 11 130761a	
	C13	Pandeya, Surendra N. et al., <i>Indian Drugs</i> (1985), 23(3), 146-51 XP0080000199	
	C14	Daidone, G. et al., Vol. 44, No. 5 (1989), pgs. 465-473, XP001053114	
	C15	The Merck Index 12 th Ed. (1996) p. 506	
	C16	Abstract corresponding to FR 2 753 970 (Document B9) 1998	
BS	C17	Abstract corresponding to WO 00/27819 (Document B12) 2000	
Examiner Signature	<i>[Signature]</i>		DATE CONSIDERED 03/17/06

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation or abstract is attached.

140357



 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>				Complete if Known	
				Application Number	10/743,613
				Filing Date	December 22, 2003
				First Name Inventor	Paul Spurr
				Group Art Unit	1614 1628
				Examiner Name	Saeed
Sheet	1	of	1	Attorney Docket Number	21436 US

NON PATENT LITERATURE DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include

copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

146808

146808